Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.42 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.42 |
| ▸ | S100A10 | P60903 | 1/20 | 0.42 |
| ▸ | TYMS | P04818 | 2/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.37 |
| ▸ | FEN1 | P39748 | 2/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18154713 | 0.84 | ALOX5AP (0.43) | PLK4ALOX5APFEN1RAB9ALMNA | |
| SCHEMBL18154846 | 0.83 | MTOR (0.41) | — | |
| SCHEMBL18154720 | 0.77 | LMNA (0.43) | ALDH1A1KDM4EALOX5APMEN1RAB9A | |
| SCHEMBL18154795 | 0.75 | NAMPT (0.38) | ALDH1A1MEN1KMT2ACYP2C9LMNA | |
| SCHEMBL18154833 | 0.74 | PIK3C3 (0.44) | ALDH1A1KDM4EALOX5APKMT2AMPO | |
| SCHEMBL30353164 | 0.74 | PIK3C3 (0.42) | ALDH1A1RAB9AKMT2ALMNATSHR | |
| SCHEMBL18154728 | 0.74 | PTGS2 (0.36) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL18154717 | 0.74 | PIK3C3 (0.42) | ALDH1A1RAB9AKMT2ALMNATSHR | |
| SCHEMBL9625568 | 0.74 | HTR6 (0.64) | HTR6ANXA2S100A10TYMSALDH1A1 | |
| SCHEMBL18154731 | 0.74 | MAPT (0.56) | TYMSALDH1A1KDM4EMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2023-03-28 | — | — | US | disclosed |
| EP-3283482-A1 | PLK4 INHIBITORS | Ludwig Institute for Cancer Research Ltd (CH) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016166604-A1 | PLK4 INHIBITORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | PLK4, PLK2, PLK3 | HTR6 3912/4885ANXA2 2097/4885S100A10 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.